天弘国证生物医药ETF发起式联接A(011040)申购赎回 |
|
报告期 |
期初总份额(份) |
期末总份额(份) |
期间总申购份额(份) |
期间总赎回份额(份) |
期间净申赎份额(份) |
净申赎比例 |
2024/3/31 |
311,039,000 |
344,401,000 |
82,476,400 |
49,114,400 |
33,362,000 |
10.73% |
2023/12/31 |
179,258,000 |
311,039,000 |
263,127,000 |
131,346,000 |
131,781,000 |
73.51% |
2023/12/31 |
260,327,000 |
311,039,000 |
90,461,700 |
39,749,200 |
50,712,500 |
19.48% |
2023/9/30 |
239,914,000 |
260,327,000 |
54,272,400 |
33,859,800 |
20,412,600 |
8.51% |
2023/6/30 |
179,258,000 |
239,914,000 |
118,393,000 |
57,737,300 |
60,655,700 |
33.84% |
2023/6/30 |
186,696,000 |
239,914,000 |
80,117,600 |
26,899,100 |
53,218,500 |
28.51% |
2023/3/31 |
179,258,000 |
186,696,000 |
38,275,700 |
30,838,200 |
7,437,500 |
4.15% |
2022/12/31 |
127,304,000 |
179,258,000 |
158,358,000 |
106,404,000 |
51,954,000 |
40.81% |
2022/12/31 |
171,930,000 |
179,258,000 |
38,816,300 |
31,488,500 |
7,327,800 |
4.26% |
2022/9/30 |
142,968,000 |
171,930,000 |
53,636,800 |
24,674,800 |
28,962,000 |
20.26% |
2022/6/30 |
127,304,000 |
142,968,000 |
65,905,300 |
50,240,700 |
15,664,600 |
12.3% |
2022/6/30 |
138,453,000 |
142,968,000 |
28,926,200 |
24,410,600 |
4,515,600 |
3.26% |
2022/3/31 |
127,304,000 |
138,453,000 |
36,979,100 |
25,830,100 |
11,149,000 |
8.76% |
2021/12/31 |
30,557,500 |
127,304,000 |
342,540,000 |
245,794,000 |
96,746,000 |
316.6% |
2021/12/31 |
101,882,000 |
127,304,000 |
48,381,200 |
22,959,600 |
25,421,600 |
24.95% |
2021/9/30 |
112,381,000 |
101,882,000 |
81,229,100 |
91,728,200 |
-10,499,100 |
-9.34% |
2021/6/30 |
30,557,500 |
112,381,000 |
212,930,000 |
131,106,000 |
81,824,000 |
267.77% |
2021/6/30 |
48,425,900 |
112,381,000 |
183,276,000 |
119,321,000 |
63,955,000 |
132.07% |
2021/3/31 |
30,557,500 |
48,425,900 |
29,653,700 |
11,785,400 |
17,868,300 |
58.47% |
*注:新浪财经提醒:以上数据由合作伙伴提供,仅供参考,交易请以正式公告数据为准。